- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Joseph Fuhr: The Immediate Economic Impact of Biosimilars May be Limited
Joseph P. Fuhr, Jr, PhD, professor emeritus, Widener University, sees a limited economic impact for biosimilars given current patent disputes.
Transcript (slightly modified)
What will be the immediate economic impact of biosimilars?
In the next few years I see very little economic impact (of biosimilars). There are currently 2 in the market and they are both risk launches. All are involved in various patent disputes and the Supreme Court is looking at 2 issues concerning the 180-day notice of entry and the other concerning whether the patent dance is mandatory.
As with any new industry, [biosimilars] will take time to develop and so their economic impact will be minimal.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
